Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
David A. Russler‐Germain, Edward R. Scheffer Cliff, Nancy L. Bartlett
Abstract
ABSTRACT: Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.
Topics & Concepts
Subgroup analysisMedicineLymphomaOncologyInternal medicineDiffuse large B-cell lymphomaChemotherapyLarge-cell lymphomaMeta-analysisLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchMonoclonal and Polyclonal Antibodies Research